GlassScriptPhysician profile
Matthew J Koch
NPI 1962420448
$2,845.91
in general payments reported to CMS, 2019-2025
33 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $270 · 2021: $59.27 · 2022: $125 · 2023: $597 · 2024: $1,009 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.43 | 2023-2025 | Jardiance |
| Amgen INC. | $259.97 | 2019-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $259.54 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $209.95 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Travere Therapeutics, INC. | $206.73 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $204.16 | 2020-2025 | Terlivaz |
| Fresenius USA Marketing, INC. | $153.84 | 2019-2024 | Velphoro |
| Abbvie INC. | $142.48 | 2023-2025 | |
| Lilly USA, LLC | $121.20 | 2023-2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $109.41 | 2019-2020 | |
| Akebia Therapeutics INC | $87.40 | 2019-2020 | |
| Vifor Pharma, INC. | $75.19 | 2019-2025 | Veltassa |
| Novo Nordisk INC | $61.59 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $60.09 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $59.28 | 2019-2024 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $53.65 | 2024 | |
| Calliditas Therapeutics US INC. | $46.70 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $45.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $45.14 | 2022-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $43.01 | 2024 | |
| Horizon Therapeutics Plc | $39.50 | 2023 | Krystexxa |
| Ardelyx, INC. | $37.44 | 2024-2025 | Ibsrela |
| Cormedix INC. | $30.50 | 2024 | Defencath |
| Braintree Laboratories, INC. | $24.46 | 2025 | Sutab |
| Integra Lifesciences Corporation | $23.24 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.39 | 2024 | Lifevest |
| Heartflow, INC. | $22.15 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.29 | 2024 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.72 | 2023 | Xifaxan |
| Scpharmaceuticals INC. | $18.00 | 2024 | |
| Mallinckrodt Enterprises LLC | $15.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2023 | Gattex |
| Shire North American Group INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.